Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > WHAT HAPPENED TO THE CHEERING SECTION?

<< Previous

Bullboard Posts

Next >>

Comment by scaleyon Apr 11, 2022 5:57pm

140 Views

Post# 34595159

RE:WHAT HAPPENED TO THE CHEERING SECTION?

Obviously, no cares what you spew. I hope you have a miserable life. Also-get much needed help for your fascination with a company whom who have zero shares. Most people are good, except you, you are an idiot

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments